Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new ...

When used responsibly botulinum toxin is very safe, but patients should be especially vigilant about cosmetic treatments done ...

Emma-Louise Lucas, a mother of one from Manchester, at just 31 received the shocking news that she had a rare type of cancer ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a nationwide open casting call in search of the next Faces of Natrelle®, encouraging women who have experienced breast reconstruction and ...

MedPharm has appointed Bill Humphries as its new CEO, marking a significant step in the company's strategic growth. The move ...

The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market rese ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

A whistleblower lost his bid to reinstate a False Claims Act suit alleging that Allergan Inc. and Adamas Pharmaceuticals Inc. fraudulently obtained patents on two drugs to combat Alzheimer’s disease.

NORTH CHICAGO, Ill., Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to ...